Ethylmorphine

DB01466

small molecule experimental illicit

Deskripsi

A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

Struktur Molekul 2D

Berat 313.3908
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

After ingestion, ethylmorphine is converted to morphine in the human liver by the CYP450-isozyme CYP2D6, similarly to codeine.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1212 Data
Buprenorphine Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Hydrocodone Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Magnesium sulfate The therapeutic efficacy of Ethylmorphine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Ethylmorphine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Orphenadrine Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Pramipexole Ethylmorphine may increase the sedative activities of Pramipexole.
Ropinirole Ethylmorphine may increase the sedative activities of Ropinirole.
Rotigotine Ethylmorphine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethylmorphine.
Sodium oxybate Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Thalidomide Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Alvimopan The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alvimopan.
Desmopressin The risk or severity of hyponatremia can be increased when Ethylmorphine is combined with Desmopressin.
Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Ethylmorphine.
Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethylmorphine.
Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Ethylmorphine.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine.
Naltrexone The therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Naltrexone.
Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.
Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Ethylmorphine.
Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Ethylmorphine.
Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethylmorphine.
Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethylmorphine.
Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Ethylmorphine.
Methadyl acetate The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Ethylmorphine.
Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethylmorphine.
Diamorphine The risk or severity of adverse effects can be increased when Diamorphine is combined with Ethylmorphine.
Bezitramide The risk or severity of adverse effects can be increased when Bezitramide is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine.
Ketobemidone The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Ethylmorphine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nicomorphine.
Meptazinol The therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carfentanil, C-11.
Meperidine The risk or severity of adverse effects can be increased when Meperidine is combined with Ethylmorphine.
Benzhydrocodone The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benzhydrocodone.
Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Ethylmorphine.
Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Ethylmorphine.
Naloxegol The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Naloxegol.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.
Succinylcholine The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ethylmorphine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethylmorphine.
Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Ethylmorphine.
Mirabegron The serum concentration of Ethylmorphine can be increased when it is combined with Mirabegron.
Mirtazapine Ethylmorphine may increase the serotonergic activities of Mirtazapine.
Fluvoxamine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Fluvoxamine.
Citalopram The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Citalopram.
Duloxetine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Duloxetine.
Sibutramine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Sibutramine.
Zimelidine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Zimelidine.
Dapoxetine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Dapoxetine.
Milnacipran The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Milnacipran.
Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Ethylmorphine.
Seproxetine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Seproxetine.
Levomilnacipran The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Levomilnacipran.
Indalpine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Indalpine.
Ritanserin The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Ritanserin.
Alaproclate The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Alaproclate.
Sertraline The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Sertraline.
Paroxetine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Paroxetine.
Ethanol Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.
Phentermine Phentermine may increase the analgesic activities of Ethylmorphine.
Pseudoephedrine Pseudoephedrine may increase the analgesic activities of Ethylmorphine.
Benzphetamine Benzphetamine may increase the analgesic activities of Ethylmorphine.
Diethylpropion Diethylpropion may increase the analgesic activities of Ethylmorphine.
Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Lisdexamfetamine.
Mephentermine Mephentermine may increase the analgesic activities of Ethylmorphine.
MMDA MMDA may increase the analgesic activities of Ethylmorphine.
Midomafetamine Midomafetamine may increase the analgesic activities of Ethylmorphine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Ethylmorphine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ethylmorphine.
Tenamfetamine Tenamfetamine may increase the analgesic activities of Ethylmorphine.

Target Protein

Mu-type opioid receptor OPRM1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 7654478
    Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjorneboe A, Christophersen AS, Bodd E, Morland J: Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20.
  • PMID: 9140136
    Xu BQ, Aasmundstad TA, Lillekjendlie B, Bjorneboe A, Christophersen AS, Morland J: Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. Pharmacol Toxicol. 1997 Apr;80(4):171-81.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Codethyline — Erfa
  • Dionina — Merck
  • Lepheton — Meda

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul